Fig. 6. CISP enhanced anti-tumor immunity in mice bearing melanoma.

a Schematic illustration showing the experiment process. Red arrows indicate the administration of nanomedicines. The dosage of SR-717 is 10 mg/kg, and tumors were irradiated with 808 nm laser for 5 min (1.0 W/cm²) at 12 h post the first injection. b Western blot analysis of p-TBK1, TBK1, p-IRF3 and IRF3 in tumors at 6 days post laser irradiation. c Flow-cytometric analysis of CD44⁺PD-L1⁺ cells in B16F10 melanoma at 6 days post laser irradiation (n = 4 mice). d Flow-cytometric analysis of CD3⁺CD8⁺ cells in B16F10 melanoma (n = 4 mice). e Flow-cytometric analysis of CD69⁺ cells in CD8 T cells in B16F10 melanoma (n = 4 mice). f Flow-cytometric analysis of Granzyme B⁺ cells in CD8 T cells in B16F10 melanoma (n = 4 mice). g Flow-cytometric analysis of Ki67⁺ cells in CD8 T cells in B16F10 melanoma (n = 4 mice). h Flow-cytometric analysis of CD3⁺CD4⁺ cells in B16F10 melanoma (n = 4 mice). i Flow-cytometric analysis of Foxp3⁺ cells in CD4 T cells in B16F10 melanoma (n = 4 mice). j–o IL-12 (j), L-6 (k), IFNγ (l), IFNβ (m), IFNα (n), and TNFα (o) in tumors at 6 days post laser irradiation (n = 6 mice). p Tumor growth curve of mice bearing melanoma. Red arrows indicate the administration of nanomedicines (n = 8 mice), and tumors were irradiated with 808 nm laser at 12 h post the first injection. q Survival curve of mice bearing melanoma, n = 8 mice. Data represent mean ± SEM (c–p). Statistical significance was determined by one-way ANOVA test in c–o, and it was two-sided and adjustments were made for multiple comparisons. Survival was measured using the Kaplan–Meier method and statistical significance was calculated by log-rank test in q. The experiments for b were repeated three times independently with similar results. Source data are provided as a Source Data file. QFN Quercetin-ferrum nanoparticles, QFN₇₁₇ QFN loaded with SR-717, nCSP normal-Cholesterol cell membrane-coated QFN₇₁₇, CSP low-cholesterol membrane-coated QFN₇₁₇, nCISP normal-Cholesterol cell membrane-coated ICB agent and QFN₇₁₇, CISP low-cholesterol membrane-coated ICB agent and QFN₇₁₇, CIP low-cholesterol membrane-coated ICB agent and QFN.